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Abstract--Intratracheal instillation of endotoxin (LPS) causes acute pulmonary 
inflammation characterized by the accumulation of plasma proteins and leukocytes 
within the pulmonary airways. The synthetic glucocorticoid dexamethasone 1) inhib- 
its the LPS-initiated vascular leak of plasma proteins into the airspace, 2) inhibits 
the LPS-initiated emigration of neutrophils and lymphocytes into the airspace in a 
dose-dependent fashion, and 3) inhibits LPS-initiated mRNA and/or bronchoalveolar 
lavage protein expression of cytokines (TNF, IL-1 and IL-6) and chemokines (MIP- 
lc~, MIP-2 and MCP-1). In conclusion, dexamethasone inhibits both the vascular and 
cellular aspects of acute inflammation by downregulation of a broad spectrum of 
inflammatory cytokines and chemokines. 
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I N T R O D U C T I O N  
Acute  inf lammation is a pa thophysio logic  response character ized by the vascular  
leakage o f  plasma proteins into tissues as well  as by the cel lular  emigrat ion o f  
neutrophils and mononuc lea r  leukocytes  f rom blood vessels  into tissues (1). 
Lipopolysacchar ide  (LPS),  the major  consti tuent o f  endotoxin ,  is a proinflam- 
matory component  o f  the cell  wal ls  o f  gram-negat ive  bacteria.  LPS causes acute 
neutrophilic inf lammation in the lung by upregulat ing proinf lammatory  cytokines  
and chemokines  such as T N F  (2-4) ,  IL-1 (2, 4, 5), C I N C  (6-7) ,  and MIP-2  
(7) as well  as the endothelial  adhesion molecule  E-select in  that is a crucial  
molecule  for neutrophil ic  emigra t ion  f rom postcapil lary venules  (8). 
The purpose o f  the present  study is to further characterize the model  o f  
intratracheal LPS-ini t ia ted acute inf lammation by reporting: 1) The kinetics of  
LPS-init iated p lasma protein exudat ion,  free elastase activity,  and elastase inhib- 
itory capacity in B A L  fluid; 2) The  ant i inf lammatory effect o f  dexamethasone  
on the vascular  and cel lular  aspects  o f  LPS-ini t ia ted acute inf lammation;  3) The  
downregulatory effects o f  dexamethasone  on LPS-ini t ia ted expression o f  endog-  
enous inf lammatory cytokines  and chemokines .  
M A T E R I A L S  A N D  M E T H O D S  
Male Lewis rats, viral antibody free, weighing approximately 225 gm and anesthesized with 
ether, were instilled intratracheally (i.t.) with LPS (Salmonella typhosa, Sigma Chem. Co., St. 
Louis, Missouri) or pyrogen-free saline in a volume of 0.5 ml as previously described (2). At 
various time points after i.t. instillation of 10 or 100 #g of LPS, bronchoalveolar lavage (BAL) was 
performed as previously described (2). The cell pellet from centrifuged BAL fluid was used to obtain 
the absolute leukocyte count and the supernatant was used for measurement of total protein, free 
elastase activity, elastase inhibitory capacity, and cytokine levels. Cytocentrifuge preparations stained 
by the Wrights-Giemsa method were used for leukocyte differentials. The antiinflammatory effect 
of dexamethasone was studied by the intratracheal coinstillation of LPS and dexamethasone (Elkins- 
Sinn, Cherry Hill, New Jersey). Statistical analysis to compare the absolute numbers of neutrophils 
in BAL fluid in the dexamethasone plus LPS-injected rats as compared to LPS alone-injected rats 
was by the two-tailed t-test for unpaired data and the results were expressed as the mean plus-or- 
minus one standard deviation. 
The total protein content in BAL fluid was measured by the Lowry method (9). Protein gel 
electrophoresis of BAL fluid was performed to characterize the protein composition of edema fluid 
(10). Free elastase activity in lung lavage fluid was measured using synthetic succinyl-trialanine- 
nitro anilide (SLAPN) as a substrate (11). Total elastase inhibitory capacity was determined by the 
ability of BAL fluid to inhibit elastase (10). Bioassays for TNF (WEHI 164, subclone 13) and 
IL-6 (B9 bioassay) were performed as previously described (12-13). 
Northern blot detection of IL-1/3 and IL-6 steady-state mRNA levels was performed as pre- 
viously described (2, 7, 14). RNase protection assay for MIP-I~ was performed using GAPDH as 
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a loading control. Reverse transcriptase polymerase chain reaction (RT-PCR) was performed with 
total RNA from the rat lung extracted with a modified guanidium method (15). RT-PCR was 
performed with the following primers obtained from rat cDNA: (TNF~ 5' 5866 GCA TGG ATC 
TCA AAG ACA ACC AAC/6233 GA ACA CCC ATT CCC TTC ACA GAG 3'; MCP-1 5' 29 
CCTCCACCACTATGCAGGTC/506 GCATCACATTCCAAATCACACTAG 3'; MIP-2 5' 27 
GCCAGCTCCTCAATG/304 CTTGCCTTTGTTCAG 3'). Beta-actin primer (Clontech, Palo Alto, 
California) served as a control. PCR was performed through 30 cycles of denaturation at 94~ for 
1 minute, oligonucleotide annealing at 55 ~ for 1 rain and extension at 72 ~ for 2 minutes. Reaction 
products were visualized by electrophoreses in 1.0% agarose gel containing ethidium bromide. 
R E S U L T S  
Kinetics of LPS-Initiated PMN Emigration, Protein Exudation, Free Elas- 
tase Activity, and the Elastase Inhibitory Capacity in BAL Fluid. PMN emi- 
gration into BAL fluid began at 1 hour and peaked at 12 hours. The PMN 
number in BAL fluid returned towards control values by 48 hours (Fig. 1). Total 
protein exudation in BAL fluid paralleled PMN emigration (Fig. 1). Protein gel 
electrophoresis showed a progressive accumulation of  proteins in BAL fluid that 
exhibited the same electrophoretic mobility as the proteins in rat serum (Fig. 
2). 
Elastase inhibitory capacity (EIC) in BAL fluid gradually increased and 
peaked at 12-24 hours after i.t. instillation of  LPS (Fig. 3). EIC paralleled the 
development of  edema. No free elastase activity was measured at any time point 
(data not shown), suggesting that endogenous elastase inhibitors are efficient in 
neutralizing elastase. 
Dexamethasone Inhibits Acute Inflammation. Dexamethasone inhibited 
LPS-initiated acute pulmonary inflammation at six hours in a dose-dependent 
manner (Table I). Intratracheal coinjection with LPS (100/zg) and dexametha- 
sone at doses of  0.01 mg (n = 6), 0.1 mg (n = 6) and 1.0 mg (n = 6) inhibited 
acute inflammation by 47 %, 67 %, and 79 %, respectively as compared to intra- 
tracheal LPS injection alone (n = 18) (p < 0.002, 0.001, and 0.0001, respec- 
tively, Table I). The absolute numbers of  neutrophils and lymphocytes serially 
enumerated at 2, 4, 6, 8, 12, 24 and 48 hours were also markedly decreased 
by dexamethasone (500/zg) as compared to LPS (100/~g) alone (Fig. 4). Dexa- 
methasone inhibited protein exudation into BAL fluid as shown by protein gel 
electrophoresis (Fig. 2). 
Dexamethasone Inhibits LPS-Initiated Expression of Cytokines and Che- 
mokines. TNF mRNA expression was not detected constitutively in whole lung 
by RT-PCR. After i.t. LPS challenge, TNF rnRNA was upregulated between 
2 and 6 hours (Fig. 5). Dexamethasone (500/zg) blocked the induction of  TNF 
mRNA (Fig. 5). Intratracheal coinstillation of  LPS and dexamethasone also 
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Fig. 1. A single intratracheal injection of LPS (100 /xg) causes accumulation of PMNs in BAL 
fluid peaking at 12 hours. The kinetics of protein exudation in edema fluid parallels the kinetics of 
neutrophilic emigration. 
decreased LPS-induced mRNA expression of the cytokines IL-1/3 and IL-6 at 6 
hours (Fig. 6). 
The bioactivity of the cytokines TNF and IL-6 in BAL fluid was measured 
at 0, 2, 4, 6, 8, 12, 24 and 48 hours (n = 3 at each time point) after the i.t. 
injection of LPS or after i.t. coinstillation of LPS and dexamethasone (500/~g). 
LPS-induced TNF in BAL fluid peaked at 6 hours and returned to near pre- 
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Fig. 2. The composition of LPS-induced edema protein in BAL fluid is shown by protein gel 
electrophoresis to be similar to the composition of plasma protein. Dexamethasone coinjected intra- 
tracheally with LPS substantially blocks plasma protein exudation. 
challenge level by 12 hours (Fig. 4). Dexamethasone prevented the LPS-induced 
elevation of TNF protein in BAL fluid by 86% (p < 0.002, Fig. 4). IL-6 
bioactivity also peaked at 6 hours (Fig. 4). Dexamethasone decreased the LPS- 
induced IL-6 level at 6 hours in BAL fluid by 65% (p < 0.007, Fig. 4). 
In addition to its downregulatory effect on cytokines, dexamethasone inhib- 
ited the expression of chemokines. Dexamethasone mildly to moderately 
decreased LPS-induced MIP-2 mRNA expression. MIP-2 was not constitutively 
expressed but was detected in abundance at 2, 4, and 6 hours after i.t. injection 
of LPS (Fig. 5). Dexamethasone almost completely inhibited LPS-induced MCP- 
1 m-RNA expression. MCP-1 was not constitutively detected and became max- 
imally expressed between 2 and 8 hours after i.t. LPS (Fig. 5). LPS-induced 
mRNA expression of MIP-lc~ was also decreased by dexamethasone (Fig. 7). 
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Fig. 3. An increase in the anti-elastase activity in BAL fluid accompanies the exudation of plasma 
proteins into BAL fluid, consistent with the fact that plasma proteins in edema fluid are a main 
source of elastase inhibitors. 
DISCUSSION 
Intratracheal instillation of LPS causes acute inflammation characterized by 
the accumulation of neutrophils and edema fluid within the intra-alveolar space. 
The kinetics of neutrophil emigration into the bronchoalveolar space parallels 
the exudation of serum proteins into BAL fluid, consistent with observations of 
previous investigators that LPS-induced exudation of edema fluid is neutrophil 
dependent (16-18). Protein gel electrophoresis of BAL fluid and serum supports 
Table I. Dexamethasone Inhibits Intratmcheal LPS-Initiated Acute Pulmonary Inflammation 
Experimental Groups n PMN x l0 6 % Inhibition p-Value 
LPS + saline 6 11.2 • 2.5 
LPS + Dex (.01 mg) 6 6.0 _+ 2.2 47% 0.002 
LPS + saline 6 13.1 _+ 3.4 
LPS + Dex (0.1 mg) 6 4.3 _+ 1.3 67% 0.001 
LPS + saline 6 14.2 + 3.1 
LPS + Dex (1.0 mg) 6 3.0 _+ 1.0 79% 0.0001 
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Fig. 4. Dexamethasone decreases the LPS-initiated emigration of neutrophils and lymphocytes into 
BAL fluid. LPS-initiated TNF and IL-6 protein expression in BAL fluid peaks at 6 hours, preceding 
the peak of protein exudation and neutrophil emigration at 12 hours. TNF and IL-6 expression are 
inhibited by dexamethasone. 
the concept that intraalveolar edema is the result of  vascular leakage of  circu- 
lating proteins. Anti-elastase activity in BAL fluid as assessed by elastase inhib- 
itory capacity rose in concert with the accumulation of  plasma proteins, consistent 
with the fact that serum proteins in edema fluid are the major source of  elastase 
inhibitors. The anti-elastase activity of  BAL fluid is extremely efficient since no 
free elastase is detectable in BAL fluid at any time point after the intratracheal 
administration of  LPS. 
The expression of  the proinflammatory cytokine TNF in BAL fluid pre- 
ceded the peak of  intraalveolar neutrophil accumulation. LPS also caused mRNA 
expression of  the C-X-C chemokines MIP-2 and MIP-lc~ and the C-C chemo- 
kine MCP-1. The expression of  these chemokines also preceded the peak of  
PMN influx into the lung. MIP-2 has previously been reported by Huang et al 
to be upregulated in LPS-induced pneumonitis (7). MCP-1 is a monocyte chemo- 
tactic and activating factor in vitro that may contribute to the influx of  mono- 
cytes in vivo (19-20). Enhanced production of  MCP-1 has been implicated in 
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HOURS AFTER INTRATRACHEAL LPS 
(-/+ DEXAMETHASONE) 
Fig. 5. Dexamethasone downregulates LPS-initiated TNFc~, MIP-2 and MCP-1 mRNA in whole 
lung RNA as shown by RT-PCR assay. 
the pathogenesis of immune complex-mediated acute inflammatory lung injury 
(21) as well as other inflammatory diseases such as rheumatoid arthritis (22). 
Acute inflammation is accompanied by the production of endogenous glu- 
cocorticoids. Dexamethasone, a pharmacologic glucocorticoid, strongly inhib- 
ited PMN emigration and was the most potent single anti-inflammatory agent 
tested in our laboratory to date in LPS-induced acute pneumonitis. The dexa- 
methasone-induced decrease in edema protein was probably, in part, indirectly 
caused by the inhibition of neutrophil emigration. Downregulation of TNF, 
IL-1, MIP-lc~, MIP-2, and MCP-1 expression by dexamethasone suggested that 
the anti-inflammatory effect of dexamethasone was exerted by the suppression 
of multiple proinflammatory cytokines, and chemokines. The dexamethasone- 
related decrease in LPS-induced IL-6 expression was most likely attributable in 
part to the downregulation of TNF which normally contributes to IL-6 up- 
regulation. 
In conclusion, LPS-induced acute inflammation in vivo is orchestrated by 
the interactions of multiple proinflammatory cytokines, chemokines and endo- 
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SIX HOURS AFTER INTRATRACHEAL INJECTION 
Fig. 6. Dexamethasone downregulates LPS-initiated IL-I/3 and IL-6 mRNA expression in whole 
lung RNA at 6 hours as shown by Northern blots. 
thelial adhesion molecules (2-8). The anti-inflammatory effect of dexamethasone 
in LPS-initiated acute inflammation appears to be mediated by the downregu- 
lation of a broad spectrum of proinflammatory molecules, suggesting an expla- 
nation for the observation that dexamethasone is a more potent antiinflammatory 
agent than previously tested therapeutics in this model that target a single proin- 
flammatory molecule. The efficacy of dexamethasone as an antiinflammatory 
HOURS AFTER INTRATRACHEAL INJECTION 
(-/+ DEXAMETHASONE) 
Fig. 7. Dexamethasone downregulates LPS-initiated MIP-I~ mRNA expression as shown by RNase 
protection assay. 
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agent in LPS-induced pneumonitis can serve as a reference for the potential 
clinical antiinflammatory utility o f  novel therapies such as specific cytokine, 
chemokine,  and adhesion molecule antagonists. 
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